PRECIGEN, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PRECIGEN, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $17.00M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $18.30M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $32.84M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $22.59M | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | $41.19M | Mar 2, 2020 |
| FY2019 | Sep 30, 2018 | $30.06M | Mar 2, 2020 |
| FY2019 | Jun 30, 2018 | $42.77M | Mar 2, 2020 |
| FY2019 | Mar 31, 2018 | $37.16M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $77.03M | Mar 1, 2019 |
| FY2018 | Sep 30, 2017 | $46.02M | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.68M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.93M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $6.23M | Mar 25, 2026 |
| FY2022 | Dec 31, 2022 | $26.91M | Mar 6, 2023 |
| FY2022 | Dec 31, 2021 | $14.27M | Mar 6, 2023 |
| FY2020 | Dec 31, 2020 | $19.33M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $23.58M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $30.42M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $29.84M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $17.00M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($250.64M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($126.24M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($95.90M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $28.32M | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | ($92.17M) | Mar 19, 2024 |
| FY2020 | Dec 31, 2020 | ($41.66M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($29.51M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($43.35M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($56.00M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($169.22M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($110.51M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($135.03M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($99.76M) | Mar 25, 2026 |
| FY2020 | Dec 31, 2020 | ($35.17M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($23.01M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($11.83M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($16.60M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($68.72M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | ($34.70M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2019 | ($21.51M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.33M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $53.07M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $48.61M | Mar 25, 2026 |
| FY2018 | Dec 31, 2018 | $404.59M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $143.21M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $112.14M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $147.48M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $58.98M | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $48.14M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $64.03M | Mar 2, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.13M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $41.29M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $40.42M | Mar 25, 2026 |
| FY2018 | Dec 31, 2018 | $137.81M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $146.10M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $142.32M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $109.06M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $63.65M | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $33.62M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $24.90M | Mar 2, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($87.83M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($68.17M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($66.93M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | ($65.05M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | ($55.77M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | ($77.02M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($135.93M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($124.24M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($103.72M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($48.99M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.58M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.54M | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $4.92M | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | $7.25M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $7.53M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $37.88M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $41.59M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $46.67M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $31.63M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.51M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $145.27M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $151.04M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $215.98M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $359.86M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $314.59M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $455.76M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $716.18M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $846.85M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $949.07M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.59M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $78.54M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $32.55M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $89.72M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $252.51M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $247.41M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $384.05M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $337.46M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $300.31M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $379.82M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.91M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $38.51M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $118.50M | Mar 25, 2026 |
| FY2025 | Dec 31, 2022 | $126.26M | Mar 25, 2026 |
| FY2024 | Dec 31, 2021 | $107.35M | Mar 19, 2025 |
| FY2023 | Dec 31, 2020 | $67.17M | Mar 19, 2024 |
| FY2022 | Dec 31, 2019 | $71.71M | Mar 6, 2023 |
| FY2019 | Dec 31, 2018 | $362.86M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $533.63M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $560.24M | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.23M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $19.14M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $26.61M | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $36.92M | Mar 19, 2025 |
| FY2022 | Dec 31, 2021 | $37.55M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $54.36M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $54.12M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $93.63M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $93.75M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $157.18M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.34B) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($2.09B) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($1.96B) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.87B) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($1.92B) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($1.82B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.65B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($1.33B) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($847.82M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($729.34M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.23M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $29.52M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $7.58M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.86M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $36.42M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $51.79M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $65.79M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $96.88M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $68.11M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $62.61M | Mar 1, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.17M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 25, 2026 |
| FY2022 | Dec 31, 2022 | $43.22M | Mar 6, 2023 |
| FY2022 | Dec 31, 2021 | $179.93M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $171.88M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $217.99M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $211.70M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $8.04M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.95M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $8.53M | Mar 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
| FY2016 | Dec 31, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Mar 1, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
| FY2016 | Dec 31, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Mar 1, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Mar 1, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 353.91M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 292.87M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 248.92M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 208.15M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 206.74M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 187.66M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 163.27M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 160.02M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 122.09M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 118.69M | Mar 1, 2018 |